Cure8 research brief
The study identifies acid ceramidase in myeloid cells as a regulator of sphingolipid metabolites and immune cell recruitment in a mouse model of chronic colitis, pointing to a possible new therapeutic target for IBD.
Researchers in IBD immunology and lipid metabolism; clinician-scientists interested in new preclinical targets; translational drug developers.
The report comes from an animal model (IL10 knockout mice) and describes a genetic, cell-type–specific loss of acid ceramidase in myeloid cells rather than a drug intervention. Results include tissue lipid changes (higher ceramides, lower S1P), reduced inflammatory markers, and fewer immune cells recruited into the colon.
The abstract frames these findings as mechanistic evidence that modulating sphingolipid metabolism in immune cells could influence intestinal inflammation. Because this is an abstract from a preclinical journal article, it does not provide clinical safety or efficacy data in people.
Findings in genetically modified mice do not directly translate into treatments; further work would be needed to test drug approaches that target acid ceramidase, and to assess safety and benefit in human studies.
Findings are from a conditional knockout mouse model (IL10−/−) reported at the abstract level in a basic-science journal. This is preclinical work and does not provide clinical trial or human safety data.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: National Institute of Diabetes and Digestive and Kidney Diseases, award R01 DK132079; National Institute of Diabetes and Digestive and Kidney Diseases, award R01 DK141491; National Institute of Diabetes and Digestive and Kidney Diseases, award R01 DK136240; National Institute of Diabetes and Digestive and Kidney Diseases, award F31 DK145020
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study proposes a new redox-regulatory pathway (Grx1–STAT6) that helps M2 macrophages drive tissue repair and colitis recovery in preclinical models, pointing to a possible new therapeutic target to promote...
The study links macrophage CD38-driven NAD depletion to intestinal inflammation and shows that restoring NAD or blocking CD38 reduced disease in experimental colitis—suggesting a new metabolic target for IBD therapies.
The study links a gut microbe (F. nucleatum) and its metabolite succinic acid to inflammatory activation of intestinal macrophages—an immune mechanism that can worsen colitis. Understanding this pathway could point...
